Compounds > semustine
Page last updated: 2024-08-16

semustine and busulfan

semustine has been researched along with busulfan in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19902 (28.57)18.7374
1990's0 (0.00)18.2507
2000's3 (42.86)29.6817
2010's2 (28.57)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M1
Lohrmann, HP1
Bibby, MC; Double, JA1
Jia, YQ; Leng, YM; Liu, T; Lu, JC; Meng, WT; Niu, T; Wang, H; Xu, CG1
Chen, ZC; Li, L; Li, QB; Xia, LH; You, Y; Zou, P1
Chen, J; Huang, H; Jiang, Y; Jin, Z; Liu, S; Ruan, J; Wu, D; Xiao, X; Zhang, L; Zhang, X1
Chen, BA; Ding, JH; Ge, Z; Sun, AN; Wu, DP; Yu, ZP1

Reviews

1 review(s) available for semustine and busulfan

ArticleYear
The problem of permanent bone marrow damage after cytotoxic drug treatment.
    Oncology, 1984, Volume: 41, Issue:3

    Topics: Animals; Antineoplastic Agents; Bone Marrow Diseases; Busulfan; Carmustine; Cell Division; Cell Survival; Cyclophosphamide; Dose-Response Relationship, Drug; Doxorubicin; Hematopoiesis; Hematopoietic Stem Cells; Humans; Melphalan; Semustine; Time Factors

1984

Other Studies

6 other study(ies) available for semustine and busulfan

ArticleYear
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
    Journal of medicinal chemistry, 2008, Nov-13, Volume: 51, Issue:21

    Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship

2008
Characterisation and chemosensitivity of a well-differentiated murine transplantable adenocarcinoma of the colon.
    British journal of cancer, 1983, Volume: 48, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Busulfan; Colonic Neoplasms; Cyclophosphamide; Dose-Response Relationship, Drug; Female; Mice; Mice, Inbred Strains; Neoplasm Transplantation; Semustine; Time Factors

1983
[Comparison of the long term results between two conditioning regimens MCC and BuCy in chronic myelocytic leukemia after allogeneic stem cell transplantation].
    Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2006, Volume: 37, Issue:2

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cyclophosphamide; Drug Administration Schedule; Female; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Melphalan; Middle Aged; Semustine; Stem Cell Transplantation; Treatment Outcome

2006
A comparative study of outcomes of idarubicin- and etoposide-intensified conditioning regimens for allogeneic peripheral blood stem cell transplantation in patients with high-risk acute leukemia.
    Acta pharmacologica Sinica, 2009, Volume: 30, Issue:10

    Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Aspergillus; Busulfan; China; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Graft Survival; Graft vs Host Disease; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Hydroxyurea; Idarubicin; Immunosuppressive Agents; Leukemia; Leukemia, Myeloid, Acute; Male; Methylprednisolone; Mucositis; Pneumonia; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Premedication; Retrospective Studies; Risk Factors; Semustine; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Whole-Body Irradiation

2009
Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.
    Annals of hematology, 2019, Volume: 98, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Autografts; Busulfan; Cyclophosphamide; Cytarabine; Disease-Free Survival; Etoposide; Female; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma; Male; Melphalan; Middle Aged; Semustine; Survival Rate; Transplantation Conditioning

2019
A New Conditioning Regimen Can Significantly Promote Post-Transplant Immune Reconstitution and Improve the Outcome of Umbilical Cord Blood Transplantation for Patients.
    Stem cells and development, 2019, 10-15, Volume: 28, Issue:20

    Topics: Adult; Anemia, Aplastic; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Cord Blood Stem Cell Transplantation; Cyclophosphamide; Cytarabine; Female; Graft Survival; Graft vs Host Disease; Granulocyte Colony-Stimulating Factor; Humans; Immune Reconstitution; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Primary Immunodeficiency Diseases; Semustine; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Unrelated Donors; Vidarabine

2019